AHRQ NSAID final report

02 Oct 2006
News

Executive Summary

Agency for Healthcare Research & Quality publishes final report on comparative effectiveness of osteoarthritis treatments. Report makes no significant departures from draft, which found that Pfizer's COX-2 inhibitor Celebrex has a safety benefit vs. non-selective NSAIDs (1"The Pink Sheet" Feb. 28, 2006, p. 23)...

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS047610

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS047610

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

AHRQ NSAID final report

News

Executive Summary

Related Content

Celebrex Shows “Overall Net Benefit” Versus NSAIDs, AHRQ Draft Report Says

Celebrex Shows “Overall Net Benefit” Versus NSAIDs, AHRQ Draft Report Says

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert